Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230373082> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4230373082 endingPage "68" @default.
- W4230373082 startingPage "65" @default.
- W4230373082 abstract "Objective: To assess the role of different hepatitis C virus (HCV) genotypes in the development of transaminase elevation after treatment with highly active antiretroviral therapy (HAART). Design: Retrospective cohort study at one referral HIV outpatient clinic. Methods: HCV genotype was determined in plasma samples from all consecutive HCV-HIV coinfected patients initiating HAART between March 1998 and January 2000. Clinical and laboratory data were recorded during the following 9 months. Severe transaminase elevation was defined as ≥ fivefold increase over upper normal limits (AIDS Clinical Trials Group grades 3 or 4) when baseline alanine transaminase (ALT) and aspartate transaminase (AST) values were normal, and as ≥ 3.5-fold increase above baseline ALT and AST values if they were abnormal. Results: Twelve of 70 subjects (17%) developed severe transaminase elevation. Their HCV genotypes were distributed as follows: type 1, 5/39 (13%); type 2, 0/3 (0%); type 3, 7/21 (33%); and type 4, 0/7 (0%). The incidence of severe transaminase elevation was significantly higher among subjects with HCV genotype 3 (HCV-3) compared with those with non-type 3 (OR, 4.4 [95%CI, 1.2-16.1]; P = .02). In the multivariate analysis, HCV-3 remained associated with severe transaminase elevation when adjusted for baseline HCV viral load and degree of immune recovery seen during follow-up evaluation. Conclusions: HCV-3 is an independent risk factor for developing severe transaminase elevation after HAART. HCV genotyping before initiating antiretroviral therapy may be useful for assessing the risk of hepatotoxicity and for choosing the most appropriate drugs to prescribe for HIV-HCV coinfected patients. Given that the best response to interferon plus ribavirin occurs in patients with HCV-3, treatment should be specially encouraged in coinfected persons carrying HCV-3." @default.
- W4230373082 created "2022-05-11" @default.
- W4230373082 creator A5009751300 @default.
- W4230373082 creator A5024021097 @default.
- W4230373082 creator A5040857112 @default.
- W4230373082 creator A5067576065 @default.
- W4230373082 creator A5074827235 @default.
- W4230373082 creator A5075118902 @default.
- W4230373082 date "2002-05-01" @default.
- W4230373082 modified "2023-10-18" @default.
- W4230373082 title "Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy" @default.
- W4230373082 doi "https://doi.org/10.1097/00126334-200205010-00008" @default.
- W4230373082 hasPublicationYear "2002" @default.
- W4230373082 type Work @default.
- W4230373082 citedByCount "13" @default.
- W4230373082 countsByYear W42303730822016 @default.
- W4230373082 crossrefType "journal-article" @default.
- W4230373082 hasAuthorship W4230373082A5009751300 @default.
- W4230373082 hasAuthorship W4230373082A5024021097 @default.
- W4230373082 hasAuthorship W4230373082A5040857112 @default.
- W4230373082 hasAuthorship W4230373082A5067576065 @default.
- W4230373082 hasAuthorship W4230373082A5074827235 @default.
- W4230373082 hasAuthorship W4230373082A5075118902 @default.
- W4230373082 hasBestOaLocation W42303730821 @default.
- W4230373082 hasConcept C126322002 @default.
- W4230373082 hasConcept C160160445 @default.
- W4230373082 hasConcept C181199279 @default.
- W4230373082 hasConcept C203014093 @default.
- W4230373082 hasConcept C2522874641 @default.
- W4230373082 hasConcept C2776408679 @default.
- W4230373082 hasConcept C2776455275 @default.
- W4230373082 hasConcept C2776877979 @default.
- W4230373082 hasConcept C2778606649 @default.
- W4230373082 hasConcept C2779679107 @default.
- W4230373082 hasConcept C2780567839 @default.
- W4230373082 hasConcept C55493867 @default.
- W4230373082 hasConcept C71924100 @default.
- W4230373082 hasConcept C86803240 @default.
- W4230373082 hasConcept C90924648 @default.
- W4230373082 hasConceptScore W4230373082C126322002 @default.
- W4230373082 hasConceptScore W4230373082C160160445 @default.
- W4230373082 hasConceptScore W4230373082C181199279 @default.
- W4230373082 hasConceptScore W4230373082C203014093 @default.
- W4230373082 hasConceptScore W4230373082C2522874641 @default.
- W4230373082 hasConceptScore W4230373082C2776408679 @default.
- W4230373082 hasConceptScore W4230373082C2776455275 @default.
- W4230373082 hasConceptScore W4230373082C2776877979 @default.
- W4230373082 hasConceptScore W4230373082C2778606649 @default.
- W4230373082 hasConceptScore W4230373082C2779679107 @default.
- W4230373082 hasConceptScore W4230373082C2780567839 @default.
- W4230373082 hasConceptScore W4230373082C55493867 @default.
- W4230373082 hasConceptScore W4230373082C71924100 @default.
- W4230373082 hasConceptScore W4230373082C86803240 @default.
- W4230373082 hasConceptScore W4230373082C90924648 @default.
- W4230373082 hasIssue "1" @default.
- W4230373082 hasLocation W42303730821 @default.
- W4230373082 hasLocation W42303730822 @default.
- W4230373082 hasOpenAccess W4230373082 @default.
- W4230373082 hasPrimaryLocation W42303730821 @default.
- W4230373082 hasRelatedWork W1556779510 @default.
- W4230373082 hasRelatedWork W1968250251 @default.
- W4230373082 hasRelatedWork W2002018939 @default.
- W4230373082 hasRelatedWork W2063752072 @default.
- W4230373082 hasRelatedWork W2092993785 @default.
- W4230373082 hasRelatedWork W2365450081 @default.
- W4230373082 hasRelatedWork W2886844653 @default.
- W4230373082 hasRelatedWork W3009562840 @default.
- W4230373082 hasRelatedWork W307921490 @default.
- W4230373082 hasRelatedWork W3149371126 @default.
- W4230373082 hasVolume "30" @default.
- W4230373082 isParatext "false" @default.
- W4230373082 isRetracted "false" @default.
- W4230373082 workType "article" @default.